Vytorin
Coronary heart disease, prophylaxis of cardiovascular event, Diabetes + 11 more
Treatment
19 FDA approvals
20 Active Studies for Vytorin
Treatment for
Coronary heart disease
What is Vytorin
Simvastatin
The Generic name of this drug
Treatment Summary
Ezetimibe is a medicine used to lower cholesterol levels. It works by blocking the absorption of cholesterol and phytosterols in the intestines. This drug was first studied in the 1990s and has been proven to be effective in treating high cholesterol levels due to primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. Unlike other cholesterol-lowering drugs such as statins and bile acid sequestrants, Ezetimibe works by targeting a specific protein called Niemann-Pick C1-Like 1 (NPC1
Zocor
is the brand name
Vytorin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zocor
Simvastatin
1991
620
Approved as Treatment by the FDA
Simvastatin, otherwise called Zocor, is approved by the FDA for 19 uses like Diabetes Mellitus and Homozygous Familial Hypercholesterolemia .
Diabetes Mellitus
Homozygous Familial Hypercholesterolemia
Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe
Hypercholesterolemia
Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe
Mixed Hyperlipidemia
Used to treat Mixed Hyperlipidemia in combination with Ezetimibe
Diet
Used to treat Diet in combination with Ezetimibe
Lipid-Lowering Therapy
Used to treat Lipid-Lowering Therapy in combination with Ezetimibe
Homozygous Familial Hypercholesterolaemia (HoFH)
Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe
history of stroke or other cerebrovascular disease cardiovascular event
prophylaxis of cardiovascular event
Heterozygous Familial Hypercholesterolemia (HeFH)
Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe
Physical Activity
Used to treat Exercise in combination with Ezetimibe
history of coronary heart disease cardiovascular event
Cardiovascular Events
cholesterol
Helps manage High Cholesterol
Peripheral Vascular Disease Patient
Diabetes
Coronary heart disease
Peripheral Vascular Disease
Cerebrovascular Disorders
Effectiveness
How Vytorin Affects Patients
Ezetimibe helps lower cholesterol levels such as total cholesterol, low-density lipoprotein cholesterol, apoprotein B, non-high-density lipoprotein cholesterol and triglycerides, while increasing the level of high-density lipoprotein cholesterol. When taken in the recommended dose, it can reduce LDL levels by 15-20% and increase HDL-C by 2.5-5%. Those with moderate-severe liver impairment should avoid taking ezetimibe, and it is important to note that there have been reports of muscle pain and damage (rhabdomyolysis) in those taking ezetim
How Vytorin works in the body
Ezetimibe works to reduce cholesterol levels by blocking a protein in the intestine that helps absorb cholesterol. Ezetimibe attaches to the protein, called NPC1L1, and prevents it from pulling cholesterol into the cell. This reduces the amount of cholesterol that is absorbed by the intestine and sent to the liver, resulting in lower cholesterol levels in the body. It is not fully understood how Ezetimibe works, but one study suggests that it prevents the NPC1L1 protein from binding to cholesterol, while another suggests that it disrupts other proteins involved in cholesterol absorption.
When to interrupt dosage
The prescribed dosage of Vytorin is contingent upon the established condition, such as Diet, Homozygous Familial Hypercholesterolemia and Hyperlipidemia. The measure of dosage alters, as per the delivery approach (e.g. Oral or Tablet), outlined in the table below.
Condition
Dosage
Administration
Mixed Hyperlipidemia
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Peripheral Vascular Disease
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Coronary heart disease
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
prophylaxis of cardiovascular event
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Diabetes
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Cardiovascular Events
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Physical Activity
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Type 2 Diabetes
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
cholesterol
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Diet
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Lipid-Lowering Therapy
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Hypercholesterolemia
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Cerebrovascular Disorders
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Homozygous Familial Hypercholesterolemia
, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL
Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular
Warnings
Vytorin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Liver Diseases
Do Not Combine
There are 20 known major drug interactions with Vytorin.
Common Vytorin Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Simvastatin.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Simvastatin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Simvastatin.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Simvastatin.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Simvastatin.
Vytorin Toxicity & Overdose Risk
The toxic dose of sitostanol in rats is greater than 2000mg/kg. In mice and dogs it is greater than 5000mg/kg and 3000mg/kg, respectively. One person has accidentally overdosed on sitostanol in clinical studies, but did not experience any adverse effects. Treatment for an overdose of sitostanol includes symptomatic care.
Vytorin Novel Uses: Which Conditions Have a Clinical Trial Featuring Vytorin?
Currently, 8 clinical trials are underway to assess the potential of Vytorin to ameliorate sitosterols, Dietary Lipids and other associated conditions.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Diabetes
74 Actively Recruiting
Phase 1, Not Applicable, Phase 4, Phase 2, Phase 3
Homozygous Familial Hypercholesterolemia
2 Actively Recruiting
Phase 3
cholesterol
4 Actively Recruiting
Phase 3, Not Applicable
prophylaxis of cardiovascular event
0 Actively Recruiting
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Hypercholesterolemia
4 Actively Recruiting
Phase 1, Phase 3
Lipid-Lowering Therapy
0 Actively Recruiting
Cerebrovascular Disorders
2 Actively Recruiting
Phase 1, Not Applicable
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Cardiovascular Events
4 Actively Recruiting
Not Applicable
Coronary heart disease
0 Actively Recruiting
Mixed Hyperlipidemia
0 Actively Recruiting
Peripheral Vascular Disease
6 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3
Vytorin Reviews: What are patients saying about Vytorin?
5
Patient Review
11/24/2012
Vytorin for High Cholesterol
5
Patient Review
9/1/2012
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
5
Patient Review
11/24/2012
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
5
Patient Review
2/18/2013
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
5
Patient Review
12/31/2011
Vytorin for Homozygous Inherited High Blood Cholesterol
4.7
Patient Review
10/1/2012
Vytorin for Homozygous Inherited High Blood Cholesterol
4.7
Patient Review
7/15/2015
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
4.3
Patient Review
8/2/2012
Vytorin for High Cholesterol
4.3
Patient Review
10/21/2011
Vytorin for Homozygous Inherited High Blood Cholesterol
4.3
Patient Review
12/20/2013
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
3.7
Patient Review
10/23/2012
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
3.7
Patient Review
11/8/2011
Vytorin for High Cholesterol
2.3
Patient Review
9/10/2012
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
2
Patient Review
12/24/2011
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
1.7
Patient Review
10/17/2011
Vytorin for Combined High Blood Cholesterol and Triglyceride Level
1.3
Patient Review
2/18/2013
Vytorin for High Cholesterol
Patient Q&A Section about vytorin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Vytorin better than Lipitor?
"The study found that VYTORIN 10/40 mg decreased LDL cholesterol by 59 percent compared to 48 percent for Lipitor 40 mg in the subgroup of high risk patients with baseline LDL cholesterol values of 169 mg/dL and 175 mg/dL respectively (p<0.001)."
Answered by AI
What are side effects of Vytorin?
"difficulty urinating,
You may experience a headache, nausea, vomiting, diarrhea, dizziness, depression, memory problems, confusion, or difficulty urinating."
Answered by AI
What is Vytorin used for?
"Simvastatin belongs to a group of drugs known as "statins." It works by reducing the amount of cholesterol made by the liver.
This combination medication helps lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. Ezetimibe works by reducing the amount of cholesterol your body absorbs from your diet. Simvastatin belongs to a group of drugs known as "statins." It works by reducing the amount of cholesterol made by the liver."
Answered by AI
What are the side effects of Vytorin?
"A headache, nausea, vomiting, diarrhea, dizziness, depression, memory problems, confusion may be caused by a concussion."
Answered by AI
What is the difference between Vytorin and Crestor?
"Vytorin was found to be more effective than Crestor at reducing LDL cholesterol by 52 to 61 percent depending on the dosage, according to a study funded by Merck and Schering-Plough."
Answered by AI
Why was Vytorin taken off the market?
"The US Food and Drug Administration (FDA) has not approved Zetia and Vytorin, Merck's medicines that are used to reduce the risk of cardiovascular events in patients with coronary heart disease. Feb 15, 2016"
Answered by AI